Gan & Lee Pharmaceuticals
SSE:603087
Income Statement
Earnings Waterfall
Gan & Lee Pharmaceuticals
Revenue
|
2.4B
CNY
|
Cost of Revenue
|
-638.9m
CNY
|
Gross Profit
|
1.7B
CNY
|
Operating Expenses
|
-1.8B
CNY
|
Operating Income
|
-9.9m
CNY
|
Other Expenses
|
250.7m
CNY
|
Net Income
|
240.8m
CNY
|
Income Statement
Gan & Lee Pharmaceuticals
Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||
Revenue |
2 192
N/A
|
3 362
+53%
|
3 441
+2%
|
3 630
+6%
|
3 673
+1%
|
3 612
-2%
|
3 753
+4%
|
2 971
-21%
|
2 346
-21%
|
1 712
-27%
|
1 580
-8%
|
2 107
+33%
|
2 381
+13%
|
|
Gross Profit | ||||||||||||||
Cost of Revenue |
(199)
|
(307)
|
(339)
|
(393)
|
(424)
|
(396)
|
(429)
|
(403)
|
(406)
|
(406)
|
(517)
|
(597)
|
(639)
|
|
Gross Profit |
1 992
N/A
|
3 055
+53%
|
3 101
+2%
|
3 237
+4%
|
3 249
+0%
|
3 216
-1%
|
3 325
+3%
|
2 568
-23%
|
1 940
-24%
|
1 306
-33%
|
1 063
-19%
|
1 510
+42%
|
1 742
+15%
|
|
Operating Income | ||||||||||||||
Operating Expenses |
(1 136)
|
(1 627)
|
(1 658)
|
(1 705)
|
(1 756)
|
(1 783)
|
(1 869)
|
(1 844)
|
(1 877)
|
(1 938)
|
(1 886)
|
(1 848)
|
(1 752)
|
|
Selling, General & Administrative |
(848)
|
(1 176)
|
(1 243)
|
(1 290)
|
(1 312)
|
(1 297)
|
(1 428)
|
(1 368)
|
(1 379)
|
(1 365)
|
(1 270)
|
(1 231)
|
(1 177)
|
|
Research & Development |
(274)
|
(391)
|
(412)
|
(456)
|
(486)
|
(437)
|
(485)
|
(496)
|
(517)
|
(520)
|
(585)
|
(580)
|
(539)
|
|
Depreciation & Amortization |
0
|
(75)
|
0
|
0
|
0
|
(92)
|
0
|
0
|
0
|
(98)
|
0
|
0
|
0
|
|
Other Operating Expenses |
(14)
|
14
|
(4)
|
40
|
41
|
43
|
45
|
20
|
19
|
45
|
(32)
|
(37)
|
(36)
|
|
Operating Income |
856
N/A
|
1 428
+67%
|
1 443
+1%
|
1 532
+6%
|
1 493
-3%
|
1 433
-4%
|
1 456
+2%
|
724
-50%
|
63
-91%
|
(631)
N/A
|
(824)
-30%
|
(338)
+59%
|
(10)
+97%
|
|
Pre-Tax Income | ||||||||||||||
Interest Income Expense |
(12)
|
24
|
94
|
10
|
140
|
266
|
142
|
300
|
184
|
103
|
177
|
134
|
186
|
|
Non-Reccuring Items |
(2)
|
0
|
1
|
3
|
3
|
(0)
|
0
|
(1)
|
(0)
|
(40)
|
1
|
1
|
1
|
|
Gain/Loss on Disposition of Assets |
0
|
(7)
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
(6)
|
0
|
0
|
0
|
|
Total Other Income |
(1)
|
(1)
|
(7)
|
(10)
|
(10)
|
(1)
|
(3)
|
(2)
|
(4)
|
(8)
|
(16)
|
(16)
|
(15)
|
|
Pre-Tax Income |
841
N/A
|
1 446
+72%
|
1 531
+6%
|
1 535
+0%
|
1 625
+6%
|
1 696
+4%
|
1 595
-6%
|
1 022
-36%
|
242
-76%
|
(582)
N/A
|
(662)
-14%
|
(219)
+67%
|
161
N/A
|
|
Net Income | ||||||||||||||
Tax Provision |
(155)
|
(215)
|
(233)
|
(240)
|
(210)
|
(243)
|
(219)
|
(140)
|
(75)
|
143
|
158
|
111
|
79
|
|
Income from Continuing Operations |
686
|
1 231
|
1 298
|
1 296
|
1 416
|
1 453
|
1 376
|
882
|
168
|
(440)
|
(504)
|
(108)
|
241
|
|
Income to Minority Interest |
0
|
0
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Net Income (Common) |
686
N/A
|
1 231
+79%
|
1 298
+5%
|
1 296
0%
|
1 416
+9%
|
1 453
+3%
|
1 376
-5%
|
882
-36%
|
168
-81%
|
(440)
N/A
|
(504)
-15%
|
(108)
+79%
|
241
N/A
|
|
EPS (Diluted) |
1.28
N/A
|
2.31
+80%
|
2.31
N/A
|
2.3
0%
|
2.52
+10%
|
2.59
+3%
|
2.45
-5%
|
1.57
-36%
|
0.3
-81%
|
-0.78
N/A
|
-0.9
-15%
|
-0.19
+79%
|
0.43
N/A
|